Danuglipron
About
About Danuglipron
Danuglipron is Pfizer's oral small-molecule GLP-1 receptor agonist, which showed meaningful weight loss in early trials but required twice-daily dosing, limiting its competitive profile versus once-daily alternatives. Pfizer paused the twice-daily program in favor of a once-daily formulation currently in development. It remains a significant entry in the oral GLP-1 space given Pfizer's manufacturing scale and distribution reach.
Science
Mechanism of Action
Acts as a non-peptide small molecule agonist at the GLP-1 receptor, mimicking endogenous GLP-1 to suppress appetite via hypothalamic pathways, slow gastric emptying, and stimulate glucose-dependent insulin release from pancreatic beta cells.
Dosing
Typical Protocol
120 mg oral twice daily (prior formulation); once-daily formulation doses under investigation.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Danuglipron — with trust scores, legal credentials, and pricing transparency.